Nevertheless, the systemic use of CD47-targeting agents is thought to be hampered by the broad expression of CD47, which is manifested by severe depletion of RBCs and platelets, leading to acute anemia and thrombocytopenia in treated patients [20, 22] and requiring substantial amounts of agent to block CD47 on all immune cells (i.e. the “antigen sink”). This evidence concerns the gene CD47 and Thrombocytopenia.